Gemini Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter ended and six month ended June 30, 2021. For the quarter, the company reported loss from operations of $16,320,000 compared to $6,666,000 a year ago. Net loss and comprehensive loss was $16,447,000 compared to $6,773,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.38 compared to $0.44 a year ago. For the six months, the company reported loss from operations of $32,810,000 compared to $16,297,000 a year ago. Net loss and comprehensive loss was $35,495,000 compared to $16,519,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.94 compared to $1.11 a year ago.